Data Sheet 1_The efficacy and safety of iguratimod treatment in stable systemic lupus eryt

A prospective cohort study of 52 adult patients with stable systemic lupus erythematosus (SLE) evaluated the efficacy and safety of iguratimod as maintenance therapy. The dataset, authored by Lei Zhang and published on figshare, includes 16 patients in the iguratimod group and 31 matched controls, with flare rates and time-to-first-flare as primary endpoints. The study found no significant difference in 52-week flare risk between the groups, with results last updated in June 2026.

Use Cases

• Compare flare rates and relapse risk between treatment groups based on the reported hazard ratios and confidence intervals.
• Analyze the safety profile of iguratimod based on the reported adverse event data.
• Model time-to-first-flare outcomes using the prospective cohort data structure.
• Benchmark maintenance therapy outcomes in stable SLE patients based on SLEDAI-2K scores.

Strengths

• Data is from a prospective cohort study with a defined 1:2 matched control group design.
• Includes specific, reported primary endpoints: 52-week flare rates of 37.5% and 29% for the treatment and control groups, respectively.
• Clear safety outcome reporting: no serious adverse events were reported for the iguratimod group.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small (296.3 KB), indicating a limited scope and sample size of 52 enrolled patients.

Provenance

Source

figshare

Collection Method

Prospective cohort study with consecutive screening of 220 patients and frequency matching.

Time Range

Study period includes a 52-week follow-up.

Freshness

Last updated 2026-06-01 04:18:56; freshness should be verified.